Although DLEU2 and SNHG3 are not related to CML directly, related materials show that DLEU2 is closely related to CLL, which provides us with new insights into ceRNA-mediated CML therapeutic regulatory mechanisms and facilitates the diagnosis of biomarkers and CML therapeutic targets. The gene discussed is DLEU2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.